Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Status and Novel Perspectives

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Status and Novel Perspectives

Immune checkpoint inhibitors (ICIs) represent a promising treatment for many kinds of cancers, including hepatocellular carcinoma (HCC). The rationale for using ICIs in HCC is based on the immunogenic background of hepatitis and cirrhosis and on the observation of high programmed death-ligand 1 (PD-...

Full description

Bibliographic Details
Main Authors: Piera Federico, Angelica Petrillo, Pasqualina Giordano, Davide Bosso, Antonietta Fabbrocini, Margaret Ottaviano, Mario Rosanova, Antonia Silvestri, Andrea Tufo, Antonio Cozzolino, Bruno Daniele
Format: Article
Language:English
Published: MDPI AG 2020-10-01
Series:Cancers
Subjects:
hepatocellular carcinoma
immunotherapy
combination therapy
predictive markers
Online Access:https://www.mdpi.com/2072-6694/12/10/3025

Internet

https://www.mdpi.com/2072-6694/12/10/3025

Similar Items